Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

1 Oct 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 31588020
DOI: 10.1016/j.ccell.2019.09.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityPMID 31588020Read ↗

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivitySemantic proximity Read ↗

Poziotinib for uncommon ERBB mutations.Semantic proximity Read ↗

NAMPT: A critical driver and therapeutic target for cancerSemantic proximity Read ↗

Mechanism of activation and the rewired network: New drug design concepts.Semantic proximity Read ↗

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsSemantic proximity Read ↗

An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.Semantic proximity Read ↗

Recurrent <i>FBXW7</i> mutations bypass Wnt/β-catenin addiction in cancerSemantic proximity Read ↗

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsSemantic proximity Read ↗

WNT-driven chromosomal instability as a biomarker for PORCN inhibitionSemantic proximity Read ↗

Members of FOX family could be drug targets of cancersSemantic proximity Read ↗

Network Pharmacology-Based Prediction of Anticancer Targets of Mebendazole: Integrating Molecular Targets, Signaling Pathways, and Clinical EvidenceSemantic proximity Read ↗

Development of a pipeline to evaluate YAP-TEAD inhibitor potential <i>-</i> direct TEAD inhibition represses cancerous growth in a <i>NF2</i> -mutant model of mesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.